Amevive

Amevive

a trademark for alefacept.
References in periodicals archive ?
She also worked briefly on Amevive and extensively on a backup to Tysabri.
When psoriasis covers large areas of the body, frequent (sometimes weekly) injections of immune-suppressing drugs, such as Amevive, Enbrel, Humira, or Remicade may be recommended.
13) systemic drugs including Amevive (alefacept), Raptiva (efalizumab), Enbrel (etanercept) and Remicade (infliximab).
It also will sell the rights to Amevive, a psoriasis drug approved in 2003 that generated $43 million in sales last year.
People coping with chronic psoriasis may benefit from weekly injections of Amevive (alefacept), a protein that treats the cause of the condition by reducing blood levels of certain immune cells called T-cells.
The non-exclusive licenses will apply to AMEVIVE (alefacept), currently approved in the United States for moderate-to-severe chronic plaque psoriasis, and other potential products in Biogen's product pipeline.
As for other biologic therapies in this class, the FDA has classified Amevive as an immunosuppressive because of its effects on T lymphocytes; treatment can increase the risk of malignancies and infections.
These Phase II data show that AMEVIVE is the first disease-modifying agent for the treatment of psoriasis that has a long duration of effect and is well tolerated.
Biogen (Nasdaq: BGEN) has announced that AMEVIVE (Recombinantly Engineered LFA-3/IgG1 Human Fusion Protein), its candidate for treatment of moderate-to-severe psoriasis, showed excellent dose response and side-effect profile in a Phase II clinical trial.
received federal approval for its Amevive drug, which treats moderate to severe psoriasis.
Food and Drug Administration approved the first biologic therapy for psoriasis, Amevive (alefacept), an injected medication.
Patient accrual for two Phase III trials with AMEVIVE, both involving patients with chronic plaque psoriasis, is well ahead of schedule.